Addus HomeCare
Scaled home-care platform compounding cash in a structurally growing niche
Addus operates a three-segment, largely U.S. Medicaid-anchored home-care platform focused on non-medical personal care, with complementary hospice and home health that broaden referral reach and payer negotiations.
Scale expanded materially with the December 2024 acquisition of Gentiva’s personal care operations across seven states, followed by smaller tuck-ins in 2025 and the HomeCourt Home Care acquisition on May 1, 2026. As of Q1 2026, Addus serves roughly 62,750 patients and consumers through 263 locations in 24 states.
TTM net service revenue is approximately 1.45 billion dollars, with gross margin near 32 percent and operating margin near 9 to 10 percent. TTM free cash flow is about 137 million dollars, aided by low capital intensity.
Net leverage is modest with cash of 103 million dollars and around 94 million dollars drawn on a 650 million dollar revolver maturing 2028. The investment case is a durable, cash-generative, asset-light consolidator in a fragmented market where states and managed care plans increasingly prefer lower-cost home and community-based services.
Key growth vectors are organic hour growth and state rate support in personal care, steady hospice improvement, disciplined M&A, and eventual value-based arrangements that reward total cost reduction.
Risks are concentrated in reimbursement and labor: the CMS Access Rule’s 80 percent direct-care compensation requirement by mid-2030, state budget cycles, managed-care contracting dynamics, labor supply and union exposure, and payer concentration in states like Illinois.
Management acknowledges these dynamics and highlights long implementation timelines and state flexibility. On balance, we see a predictable cash generator with prudent leverage and measured capital deployment.
Does Addus HomeCare have a strong competitive moat?
Addus benefits from scale in a fragmented, operationally intensive niche where compliance, billing, scheduling, and managed-care contracting capabilities matter.
The 2024 Gentiva personal care acquisition and 2025–2026 tuck-ins broadened density and payer reach, and offering three levels of care in select markets increases negotiating leverage and cross-referrals.
Nonetheless, switching costs for consumers are moderate, network effects are limited, and state-set or plan-set pricing constrains classical pricing power.
Moat sub-scores and weights we apply: cost advantage 75/100 (30 percent weight) via SG&A leverage and shared back office; switching costs 65/100 (30 percent) given caregiver-client relationships and MCO contracting frictions; intangible assets 65/100 (20 percent) including state relationships/licensure and reputation; efficient scale 70/100 (10 percent) in certain local markets; network effects 20/100 (10 percent).
Weighted result about 64. Future moat trajectory depends on building deeper multi-service density and value-based contracts.
Does Addus HomeCare have pricing power in its industry?
Personal care rates are largely set by states or negotiated with managed Medicaid, which curbs unilateral price increases. Addus can achieve effective pricing through state rate wins, favorable MCO mix, and contractual escalators, but not classic discretionary pricing.
Examples include Texas’ 9.9 percent rate increase effective September 1, 2025, and Illinois rate support, both helpful but policy-driven. Hospice and home health pricing are influenced by Medicare rules.
Upcoming CMS Access Rule requirements on 80 percent caregiver compensation will likely hard-cap margin expansion potential in personal care, raising the bar on operating efficiency. Taken together, pricing capacity is present but mostly externally mediated, not company-driven.
How predictable is Addus HomeCare's business?
Revenue is predominantly recurring and hours-based, with reimbursement visibility and stable payer flows across states and managed care. Q1 2026 net service revenue grew 7.7 percent year on year, and TTM operating margins have trended around 9 to 10 percent, producing steady free cash conversion.
Diversification across 24 states and three segments enhances stability, though regulatory and payer changes can introduce step-changes. Hospice trends improved in 2025, and management continues to emphasize organic growth and selective acquisitions.
We view long-term demand visibility as high given aging demographics and policy preference for HCBS, offset by periodic reimbursement resets.
Is Addus HomeCare financially strong?
Balance sheet conservatism is a core strength. At March 31, 2026, cash was 103.1 million dollars with about 94.3 million dollars outstanding on a 650 million dollar revolver, leaving ample liquidity and low net leverage.
The facility matures in July 2028. TTM free cash flow is approximately 137 million dollars, with capex near 8 million dollars and no heavy fixed asset base. Accounts receivable days are reasonable, although the Illinois Department on Aging remains a sizeable receivable concentration to monitor.
Overall resilience to shocks is strong given cash generation, liquidity, and flexible cost structure.
How effective is Addus HomeCare's capital allocation strategy?
Management has executed a disciplined roll-up strategy: Gentiva personal care in December 2024 to expand scale, followed by 2025 tuck-ins and HomeCourt Home Care on May 1, 2026. The June 2024 equity raise prudently funded growth while keeping leverage contained. 2025 operating cash flow was 111.5 million dollars with roughly 7.7 million dollars of capex, highlighting strong reinvestable cash.
Stock-based compensation at 16.4 million dollars in 2025 is material but acceptable for a services consolidator; share count has risen modestly due to equity financing and awards.
We see M&A returns as attractive given integration track record, state selection, and SG&A leverage, with attention to payer and labor dynamics in acquired markets.
Does Addus HomeCare have high-quality management?
Led by long-tenured CEO Dirk Allison with an experienced CFO and operating leaders, Addus has consistently balanced organic growth with disciplined acquisitions and conservative leverage. The team’s state-by-state strategy and focus on markets with constructive Medicaid dynamics reflect sound judgment.
Labor relations require ongoing attention given roughly one third of employees represented by unions and industry-wide caregiver turnover pressures, but management has navigated wage, volume, and rate complexity effectively.
Is Addus HomeCare a quality company?
Addus HomeCare is a good quality company with a quality score of 78/100
- Scaled Medicaid HCBS platform with complementary hospice and home health enhances payer negotiations and referral capture, now spanning 24 states and 263 locations after Gentiva personal care and subsequent tuck-ins.
- TTM free cash flow about 137 million dollars on low capex, with net debt roughly neutral and a 650 million dollar revolver available through 2028, supporting a steady roll-up strategy.
- Regulatory overhang from the CMS Access Rule’s 80 percent pass-through for HCBS by mid-2030 appears manageable over a long runway, but it caps margin expansion and raises execution demands state by state.
- Organic drivers include favorable state rate actions (for example, Texas in 2025) and stable personal care volumes; hospice shows improving organic growth and operating leverage.
- Labor remains the swing factor: mixed caregiver satisfaction and meaningful union exposure require continued wage investment and workforce management to sustain growth.
What is the fair value of Addus HomeCare stock?
Is Addus HomeCare a good investment at $107?
The following analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment advice, or a recommendation to buy or sell any security. The opinions expressed are based on publicly available information and historical data. Beanvest and its contributors may hold positions in the securities mentioned. Investors should conduct their own due diligence or consult a licensed financial advisor before making any investment decision.